Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

OTO-201 for the Treatment of Acute Otitis Externa: Results from a Phase 3 Randomized Clinical Study.

Ansley J, Mair EA, Namini H, Lu CH, LeBel C.

Ann Otol Rhinol Laryngol. 2019 Mar 2:3489419830116. doi: 10.1177/0003489419830116. [Epub ahead of print]

PMID:
30829050
2.

Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.

Janssen RS, Mangoo-Karim R, Pergola PE, Girndt M, Namini H, Rahman S, Bennett SR, Heyward WL, Martin JT.

Vaccine. 2013 Nov 4;31(46):5306-13. doi: 10.1016/j.vaccine.2013.05.067. Epub 2013 May 30.

PMID:
23727422
3.

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.

Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, Bennett S, Janssen RS, Namini H, Martin JT.

Vaccine. 2013 Nov 4;31(46):5300-5. doi: 10.1016/j.vaccine.2013.05.068. Epub 2013 May 30.

PMID:
23727002
4.

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine.

Sablan BP, Kim DJ, Barzaga NG, Chow WC, Cho M, Ahn SH, Hwang SG, Lee JH, Namini H, Heyward WL.

Vaccine. 2012 Mar 30;30(16):2689-96. doi: 10.1016/j.vaccine.2012.02.001. Epub 2012 Feb 14.

PMID:
22342916
5.

Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery.

Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, Namini H, Hamdan AD, Roddy SP, Belkin M, Berceli SA, DeMasi RJ, Samson RH, Berman SS; PREVENT III Investigators.

J Vasc Surg. 2006 Apr;43(4):742-751; discussion 751.

6.

Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial.

Conte MS, Bandyk DF, Clowes AW, Moneta GL, Namini H, Seely L.

J Vasc Surg. 2005 Sep;42(3):456-64; discussion 464-5.

7.

Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.

Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann HL, Samuel D, Zeuzem S, Lilly L, Rendina M, Villeneuve JP, Lama N, James C, Wulfsohn MS, Namini H, Westland C, Xiong S, Choy GS, Van Doren S, Fry J, Brosgart CL; Adefovir Dipovoxil Study 435 International Investigators Group.

Hepatology. 2003 Dec;38(6):1419-27.

PMID:
14647053
8.

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.

Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, Brosgart C, Fry J, Namini H, Katlama C, Poynard T.

Lancet. 2001 Sep 1;358(9283):718-23.

PMID:
11551579
9.

Generalized ridge analysis with application to population pharmacokinetics/dynamics.

Minor JM, Namini H, Watson GA.

J Biopharm Stat. 1996 Mar;6(1):105-14.

PMID:
8838782
10.

Analysis of clinical data using neural nets.

Minor JM, Namini H.

J Biopharm Stat. 1996 Mar;6(1):83-104.

PMID:
8838781

Supplemental Content

Loading ...
Support Center